Tanzania Accelerates Pharmaceutical and Healthcare Manufacturing Investment
The Government of Tanzania, through its Ministry of Health (MoH), is proactively seeking to attract investment in its healthcare sector. In January 2026, the MoH hosted the inaugural Tanzania Pharmaceutical Production Investment Forum, convening both local and international investors to promote and expand domestic manufacturing of healthcare products.
At the forum, the Ministry highlighted strategic investment priorities, including the production of antiretroviral (ARV) medicines, vaccines for cancer and tuberculosis, cardiovascular drugs, pharmaceutical packaging, and medical devices.
Additionally, the Ministry announced a USD 10 million co-financing commitment to support a public–private partnership to construct a vaccine research laboratory, underscoring the government’s commitment to strengthening local pharmaceutical and research capacity.
The following U.S. export opportunities emerge as strong complements to Tanzania’s priority healthcare and pharmaceutical industries:
1. Pharmaceutical Manufacturing Technologies
U.S. companies are well-positioned to provide advanced drug manufacturing equipment, including formulation, filling, sterilization, and quality control systems. This capability is especially significant for the local production of antiretroviral drugs, cardiovascular medicines, and other essential pharmaceuticals, where compliance with international Good Manufacturing Practice (GMP) standards is paramount.
2. Vaccine Research and Development Infrastructure
The planned vaccine research laboratory presents opportunities for U.S. exports of laboratory technologies including bioreactors, cold-chain systems, diagnostic instruments, biosafety equipment, and clinical trial management software. U.S. expertise in vaccine R&D, including mRNA and recombinant technologies, would significantly strengthen Tanzania’s research and production capacity.
3. Medical Devices and Diagnostics
As Tanzania seeks to expand local production of medical devices, U.S. firms can export precision manufacturing equipment, testing and calibration technologies, imaging components, and digital health solutions that support diagnostics, monitoring, and treatment of cardiovascular diseases, cancer, and infectious diseases.
4. Pharmaceutical Packaging Technologies
There is strong demand for U.S.-made packaging machinery, serialization and traceability systems, anti-counterfeiting technologies, and sustainable packaging solutions that meet international regulatory and export requirements.
5. Regulatory, Quality Assurance, and Compliance Solutions
U.S. providers can offer regulatory consulting services, validation software, laboratory information management systems (LIMS), and training programs to help Tanzanian manufacturers meet WHO prequalification, FDA standards, and regional export requirements.
6. Cold Chain and Supply Chain Technologies
Vaccine and biologics manufacturing will require robust cold-chain logistics. U.S. exports of temperature-controlled storage systems, refrigerated transport solutions, monitoring sensors, and supply-chain management software can play a critical role in ensuring product integrity.
Collectively, these technologies position U.S. companies as strategic partners in Tanzania’s effort to build a resilient, high-quality pharmaceutical and healthcare manufacturing ecosystem.
For additional business insights and to analyze your company’s prospects in this growing region, contact Commercial Specialist Athanasius Lupatu at the U.S. Commercial Service, U.S. Embassy, Dar es Salaam Athanasius.Lupatu@trade.gov.